Laura Chang, PhD, serves as VP of Business Strategy at ArteraAI. In her work prior to joining ArteraAI, she developed prognostic and predictive biomarkers in oncology, with research published in journals such as the Journal of Clinical Oncology, Lancet Oncology, and JAMA Oncology. She served as President of PFS Genomics, a start-up that developed predictive biomarkers for radiation therapy benefit in breast cancer and led its acquisition to Exact Sciences, where she worked to integrate the biomarkers into the product pipeline. At ArteraAI, Laura oversees the end-to-end product strategy, and is excited for the opportunity to improve patient care with novel AI-based tools.